STOCK TITAN
  1. Home
  2. OXFD

Oxford Immunotec (OXFD) Stock Price, News & Analysis

OXFD NASDAQ
Published by Stock Titan Data refreshed

What Changed

Price Move History

Daily moves over 5%
20 253 sessions, March 5, 2020 to March 5, 2021
Largest daily move
+26.5% close of January 7, 2021
1-year change
+64.8% closing prices, March 5, 2020 to March 5, 2021
1-month change
+0% closing prices, February 5, 2021 to March 5, 2021

Company Description

OXFD has gained 64.8% over the past year. The last closing price was $21.99.

This page collects what Stock Titan holds for OXFD, including price data and latest news.

Stock Performance

Chart
$—
-
-
Last updated:
+64.8%
Performance 1 year
-
Market Cap
-
Shares outstanding

Oxford Immunotec (OXFD) closed at $21.99 on March 5, 2021. Over the past 12 months, the price has gained 64.8%.

See what a $1,000 investment in OXFD would be worth today

Average down calculator for OXFD

OXFD Metrics & Rankings

Month to date
+0.2%
View ranking
YTD
+25.9%
View ranking

Price returns through March 5, 2021. Month-to-date and YTD include the first trading day. Ranking links may use different dates.

Latest News

View All
+0.05%

Oxford Immunotec Submits Emergency Use Authorization Request to the FDA and CE Marks T-SPOT®.COVID, a Test for the Detection of a Cell Mediated (T cell) Immune Response to SARS-CoV-2 Infection

fda approval covid-19
-0.27%

Oxford Immunotec Enters a Memorandum of Understanding (MOU) with GC MS (Green Cross Medical Science Corp. – South Korea) to Market the T-SPOT® Discovery SARS-CoV-2 Kit, for the Measurement of the T Cell Immune Response to SARS-CoV-2 Infection, in South Korea

0.00%

Oxford Immunotec Updates Their T-SPOT® Discovery SARS-CoV-2 Kit and Include a New Panel to Detect T Cells Reactive to Endemic Coronaviruses

-0.23%

New Monthly Series Spotlights What 100 Physicians Find to be Critical Needs in Their Battle Against COVID-19

covid-19
-0.90%

Oxford Immunotec’s T-SPOT® Discovery SARS-CoV-2 Test is Used to Measure the Efficacy of Valneva’s VLA2001 COVID-19 Vaccine Candidate in a Phase I/II Clinical Study

clinical trial covid-19
+26.52%

PerkinElmer to Acquire Oxford Immunotec Global PLC

acquisition
+1.48%

Oxford Immunotec Announces the Foundation of the Global T Cell Expert Consortium, Whose First Meeting Took Place This Week

+0.82%

Oxford Immunotec Announces the Approval of the T-Cell Select™ Reagent Kit, Used to Automate the T-SPOT®.TB Test Workflow, for IVD Use in South Korea

+0.48%

Oxford Immunotec Signs Exclusive Distributor Agreement with RIKEN Genesis, a Subsidiary of Sysmex, to Market the T-SPOT® Discovery SARS-CoV-2 Kit for the Measurement of the T cell Immune Response to SARS-CoV-2 Infection in Japan

-0.15%

Oxford Immunotec to Hold a Virtual Investor Event on December 17, 2020

Oxford Immunotec has 10 recent news articles. Of the recent coverage, 5 articles coincided with positive price movement and 4 with negative movement. Key topics include fda approval, covid-19, clinical trial, acquisition. View all OXFD news →

SEC Filings

View All

No SEC filings available for OXFD.

Frequently Asked Questions

What is the current quoted price of Oxford Immunotec (OXFD)?

The current quoted price of Oxford Immunotec (OXFD) is $21.99 as of March 5, 2021.